Home β€Ί Stock analysis β€Ί AXSM

Axsome Therapeutics (AXSM) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

AXSM dips 2.9% to $157.14. Closed at $157.14, -2.87% vs the prior close of $161.79. Day range $156.09–$160.43, opened at $160.43.

Last close$157.14-2.87%
Day range156.09–160.43
Open160.43
Volume873.08K
52-week range123.50–260.19
Avg volume (20d)879.18K

AXSM daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” AXSM dips 2.9% to $157.14
Oct 15, 2026 β€” AXSM ends flat (-0.3%) to $161.79
Oct 14, 2026 β€” AXSM jumps 3.8% to $162.22
Oct 13, 2026 β€” AXSM slides 5.8% to $156.32, a 6-month low on 1.8x normal volume
Oct 12, 2026 β€” AXSM dips 1.4% to $166.00, a 6-month low, 12 down days in a row
Oct 9, 2026 β€” AXSM dips 1.0% to $168.35, a 6-month low, 11 down days in a row
Oct 8, 2026 β€” AXSM dips 1.7% to $170.08, a 6-month low, 10 down days in a row
Oct 7, 2026 β€” AXSM dips 0.8% to $172.97, a 6-month low, 9 down days in a row
Oct 6, 2026 β€” AXSM dips 1.5% to $174.34, a 3-month low on 2.0x normal volume
Oct 5, 2026 β€” AXSM dips 1.2% to $177.08, a 3-month low, 7 down days in a row
Oct 2, 2026 β€” AXSM dips 1.5% to $179.25, a 3-month low, 6 down days in a row

AXSM latest news & SEC filings

Every SEC filing by or about AXSM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Sep 3, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.

Source: SEC EDGAR filing 0001193125-26-382277

Sep 3, 2026 Β· Form 144 β€” Planned insider sale

Notice of proposed sale (Form 144) β€” an insider or affiliate plans to sell restricted or control shares

A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.

Source: SEC EDGAR filing 0001958244-26-000571

Aug 10, 2026 Β· Form 10-Q β€” Quarterly report

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2026:

Source: SEC EDGAR filing 0001193125-26-342360

Aug 10, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

This is a results-day filing: the earnings press release is attached as an exhibit.

Source: SEC EDGAR filing 0001193125-26-341206

Aug 7, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.

Source: SEC EDGAR filing 0001193125-26-340688

Aug 6, 2026 Β· Form 144 β€” Planned insider sale

Notice of proposed sale (Form 144) β€” an insider or affiliate plans to sell restricted or control shares

A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.

Source: SEC EDGAR filing 0001958244-26-000491

Aug 5, 2026 Β· Form 144 β€” Planned insider sale

Notice of proposed sale (Form 144) β€” an insider or affiliate plans to sell restricted or control shares

A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.

Source: SEC EDGAR filing 0001958244-26-000488

Jul 27, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0002012383-26-002197

Jul 15, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001193125-26-304039

Jul 1, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.

Source: SEC EDGAR filing 0001193125-26-292985

Things to know before you trade AXSM

AXSM market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 2026160.43160.43156.09157.14873.08K
Oct 15, 2026163.44169.96160.27161.79802.60K
Oct 14, 2026156.44164.00155.18162.22893.20K
Oct 13, 2026166.01166.55155.68156.321.33M
Oct 12, 2026169.50170.80165.02166.00663.00K
Oct 9, 2026170.18170.64166.12168.35894.50K
Oct 8, 2026170.09172.27166.21170.081.07M
Oct 7, 2026174.00177.91172.48172.97887.30K
Oct 6, 2026176.52176.52169.30174.341.37M
Oct 5, 2026179.25179.70175.73177.08858.90K
Oct 2, 2026182.55182.55175.46179.25981.40K
Oct 1, 2026184.39185.67181.75182.07660.20K
Sep 30, 2026186.51188.00184.00184.391.03M
Sep 29, 2026191.41194.25182.10186.141.58M
Sep 28, 2026194.98198.96193.11193.89707.40K
Sep 25, 2026197.68201.42194.35195.09838.20K
Sep 24, 2026193.02197.11190.72196.03386.10K
Sep 23, 2026204.01204.70189.05193.45913.00K
Sep 22, 2026205.68207.01202.52203.10299.80K
Sep 21, 2026208.17210.85203.38205.49543.50K

About Axsome Therapeutics

Axsome Therapeutics (AXSM) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1579428.

AXSM board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Mark ColemanDirectorJun 10, 2026
Roger JeffsDirectorJun 11, 2026
Susan MahonyDirectorJun 10, 2026
Mark E SaadDirectorJun 10, 2026
Herriot TabuteauChief Executive OfficerAug 7, 2026

Executive officers

NameTitleLatest filing
Mark L. JacobsonChief Operating OfficerSep 3, 2026
Ari MaizelChief Commercial OfficerApr 23, 2026
Hunter R. MurdockGeneral CounselApr 23, 2026
Nick PizzieChief Financial OfficerJun 9, 2026
Herriot TabuteauChief Executive OfficerAug 7, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
Sep 3, 2026Mark L. JacobsonSale10,000$208.65
Sep 3, 2026Mark L. JacobsonSale10,000$208.65
Sep 3, 2026Mark L. JacobsonSale10,000$208.65
Sep 3, 2026Mark L. JacobsonSale10,000$208.65
Aug 6, 2026Herriot TabuteauSale4,660$213.95
Aug 6, 2026Herriot TabuteauSale4,660$213.95
Aug 6, 2026Herriot TabuteauSale4,660$213.95
Aug 6, 2026Herriot TabuteauSale4,660$213.95
Aug 5, 2026Herriot TabuteauSale45,004$212.01
Aug 5, 2026Herriot TabuteauSale45,004$212.01
Aug 5, 2026Herriot TabuteauSale45,004$212.01
Aug 5, 2026Herriot TabuteauSale45,004$212.01
Jul 1, 2026Herriot TabuteauSale49,666$240.25
Jul 1, 2026Herriot TabuteauSale49,666$240.25
Jul 1, 2026Herriot TabuteauSale49,666$240.25

AXSM financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$638.50M$-183.17M-3.68$-93.41M
Dec 31, 2024$385.69M$-287.22M-5.99$-128.41M
Dec 31, 2023$270.60M$-239.24M-5.27$-145.08M
Dec 31, 2022$50.04M$-187.13M-4.60$-116.51M
Dec 31, 2021β€”$-130.40M-3.47$-108.23M

Latest balance sheet: total assets $761.45M, total liabilities $678.14M, cash $319.85M (as of Jun 30, 2026).

AXSM earnings / results-day log

DateFilingClose that day
Aug 10, 20268-K Item 2.02 (results)$220.89
May 4, 20268-K Item 2.02 (results)$223.70
Feb 23, 20268-K Item 2.02 (results)$174.76
Jan 12, 20268-K Item 2.02 (results)$176.82
Nov 3, 20258-K Item 2.02 (results)$135.75
Aug 4, 20258-K Item 2.02 (results)$106.54
May 5, 20258-K Item 2.02 (results)$116.49
Feb 18, 20258-K Item 2.02 (results)$128.09
Jan 13, 20258-K Item 2.02 (results)$89.27
Nov 12, 20248-K Item 2.02 (results)$99.49
Aug 5, 20248-K Item 2.02 (results)β€”
May 6, 20248-K Item 2.02 (results)β€”

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on AXSM

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.